Trials / Recruiting
RecruitingNCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib Hydrochloride Capsule | Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously. |
Timeline
- Start date
- 2023-06-19
- Primary completion
- 2027-06-01
- Completion
- 2028-12-01
- First posted
- 2023-04-26
- Last updated
- 2023-07-25
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05830500. Inclusion in this directory is not an endorsement.